Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Trial · NCT00312845
Adverse events252
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 252
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Thrombocytopenia | Blood and lymphatic system disorders | Bortezomib + Rituximab | 32 | 334 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Rituximab | 13 | 339 | |
| other | Chills | General disorders | Bortezomib + Rituximab | 28 | 334 | |
| other | Chills | General disorders | Rituximab | 17 | 339 | |
| other | Fatigue | General disorders | Bortezomib + Rituximab | 75 | 334 | |
| other | Fatigue | General disorders | Rituximab | 27 | 339 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Bortezomib + Rituximab | 37 | 334 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Rituximab | 25 | 339 | |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | Bortezomib + Rituximab | 46 | 334 | |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | Rituximab | 15 | 339 | |
| other | Headache | Nervous system disorders | Bortezomib + Rituximab | 42 | 334 | |
| other | Headache | Nervous system disorders | Rituximab | 24 | 339 | |
| other | Paraesthesia | Nervous system disorders | Bortezomib + Rituximab | 39 | 334 | |
| other | Paraesthesia | Nervous system disorders | Rituximab | 10 | 339 | |
| other | Insomnia | Psychiatric disorders | Bortezomib + Rituximab | 30 | 334 | |
| other | Insomnia | Psychiatric disorders | Rituximab | 18 | 339 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Bortezomib + Rituximab | 51 | 334 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Rituximab | 31 | 339 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Bortezomib + Rituximab | 25 | 334 | |
| other | Pruritus | Skin and subcutaneous tissue disorders | Rituximab | 15 | 339 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00312845/events